Digital
15th -16th March 2022

3rd Edition MarketsandMarkets Orphan Drugs and Rare Diseases Virtual Conference [Time Zone - Central European Time (CET)]

New medicine for Orphan and Rare Diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.

The 3rd Annual MarketsandMarkets Orphan Drugs and Rare Diseases Conference Virtual Event is scheduled to be held on 15th -16th March 2022 will provide valuable and necessary platform for uplifting knowledge at the forefront of drug analysis.

Over the course of the conference, internationally renowned speakers can describe how their analysis journeys have developed the response towards up-to-date challenges. The attending specialists and trade partners will offer an incredible networking expertise.

This conference will gather scientists, researchers, entrepreneurs, academicians, medical officers, CEO’s, CSO’s and technologists from everywhere around the globe to discuss on the newest scientific advances within the field of rare diseases & orphan drugs that facilitate to form current and future challenges in drug analysis.

WHAT TO EXPECT
KEY HIGHLIGHTS
  • Current Orphan Drugs landscape and implications of COVID19
  • Study worldwide patterns in uncommon infections and its advances in the remedial and demonstrative market
  • Finding innovative and alternative ways in funding the development of Orphan Drugs
  • How is FDA managing orphan drugs during the pandemic?
  • The growth of orphan drugs for rare diseases
  • Challenges and opportunities in treatment
  • Improving clinical trials for rare diseases
Who Should Attend?

Academia & CEOs, Owners, Business Heads, VPs, Directors, Heads, Managers 

From the Departments of: 

  • Personalized & Innovative Medicine
  • External R&D Innovation
  • Regenerative Medicine
  • Rare and Ultra-Rare Diseases
  • Cell and Gene Therapy
  • Molecular Geneticist
  • Translational Science
  • Patient Advocacy Groups
  • Program Management
  • Public, Regulatory, Medical   Affairs
  • Patient Engagement
  • Market Access
  • Clinical Research Organizations
  • Health Economics Outcomes Research
  • Investments and Funding
  • Business Planning and Operations
  • Specialty Pharmacies
Why attend?
  • 100+ experts attending
  • Participate in constructive discussion with leading industry experts and decision-makers from pharmaceutical manufacturers who will tackle the most important issues in Rare disease diagnosis.
  • Best opportunity to showcase your work and research in front of industry leaders.
  • Develop your skills by learning new competencies and acquire knowledge from pioneers all around the world.
CONFERENCE AGENDA
CONFERENCE SPEAKERS
Advisors
June Sanson

June Sanson

Senior Director, Patient Advocacy and Industry Relations
Acadia Pharmaceuticals Inc.

June Sanson

Senior Director, Patient Advocacy and Industry Relations
Acadia Pharmaceuticals Inc.
Rudiger Schulze

Rudiger Schulze

Vice President and General Manager, Germany and Central / Eastern Europe
Ultragenyx Pharmaceutical Inc.

Rudiger Schulze

Vice President and General Manager, Germany and Central / Eastern Europe
Ultragenyx Pharmaceutical Inc.
 Dairine Dempsey

Dairine Dempsey

Non-Executive Director/Consultant
OmniSpirant Limited | Soleno Therapeutics, Inc.

Dairine Dempsey

Non-Executive Director/Consultant
OmniSpirant Limited | Soleno Therapeutics, Inc.
Speakers
June Sanson

June Sanson

Senior Director, Patient Advocacy and Industry Relations
Acadia Pharmaceuticals Inc.

June Sanson

Senior Director, Patient Advocacy and Industry Relations
Acadia Pharmaceuticals Inc.
Rudiger Schulze

Rudiger Schulze

Vice President and General Manager, Germany and Central / Eastern Europe
Ultragenyx Pharmaceutical Inc.

Rudiger Schulze

Vice President and General Manager, Germany and Central / Eastern Europe
Ultragenyx Pharmaceutical Inc.
 Dairine Dempsey

Dairine Dempsey

Non-Executive Director/Consultant
OmniSpirant Limited | Soleno Therapeutics, Inc.

Dairine Dempsey

Non-Executive Director/Consultant
OmniSpirant Limited | Soleno Therapeutics, Inc.
Mariusz Olejniczak

Mariusz Olejniczak

Chief Executive Officer
WPD Pharmaceuticals Inc

Mariusz Olejniczak

Chief Executive Officer
WPD Pharmaceuticals Inc
Andreas Uttenweiler

Andreas Uttenweiler

Head of Patient Value Access & Public Affairs
Takeda Pharmaceuticals

Andreas Uttenweiler

Head of Patient Value Access & Public Affairs
Takeda Pharmaceuticals
Shailesh Agarwal

Shailesh Agarwal

Assistant Professor of Surgery
Harvard Medical School, Partner, Mainspring Venture Partners

Shailesh Agarwal

Assistant Professor of Surgery
Harvard Medical School, Partner, Mainspring Venture Partners
Subir Roy

Subir Roy

Associate Director for Global Medical Affairs |Project Lead
MIT-Takeda Program on Fabry

Subir Roy

Associate Director for Global Medical Affairs |Project Lead
MIT-Takeda Program on Fabry
Davy Yeung

Davy Yeung

 Managing Director and Vice President of Operations
Tailored Clinical Research Solutions (TCRS)

Davy Yeung

 Managing Director and Vice President of Operations
Tailored Clinical Research Solutions (TCRS)
SPONSORS
Sponsors & Exhibitors
example-image

TCRS (Tailored Clinical Research Solutions)

Visiting Partners
example-image

Angelini

PAST EVENT GALLERY